| http://purl.uniprot.org/citations/16820285 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16820285 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16820285 | http://www.w3.org/2000/01/rdf-schema#comment | "Cytochrome P450 (CYP) omega-oxidases convert arachidonic acid (AA) to 20-hydroxyeicosatetraenoic acid (20-HETE), a lipid mediator that modulates vascular tone. We observed that a microsomal preparation containing recombinant human CYP4F3B, which converts AA to 20-HETE, converted eicosapentaenoic acid (EPA) to 20-OH-EPA. Likewise, docosahexaenoic acid (DHA) was converted to 22-OH-DHA, indicating that human CYP4F3B also can oxidize 22-carbon omega-3 fatty acids. Consistent with these findings, addition of 0.5-5 microM EPA, DHA or omega-3 docosapentaenoic acid (DPA) to incubations containing 0.5 microM [3H]AA inhibited [3H]20-HETE production by 15-65%. [3H]20-OH-EPA was rapidly taken up by COS-7 cells, and almost all of the incorporated radioactivity remained as unmodified 20-OH-EPA. The 20-OH-EPA stimulated luciferase activity in COS-7 cells that express peroxisome proliferator-activated receptor alpha, indicating that this EPA metabolite may function as a lipid mediator. These findings suggest that some functional effects of omega-3 fatty acid supplementation may be due to inhibition of 20-HETE formation or the conversion of EPA to the corresponding omega-oxidized product."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.plefa.2006.05.005"xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.plefa.2006.05.005"xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Hu S."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Hu S."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Fang X."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Fang X."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Falck J.R."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Falck J.R."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Harmon S.D."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Harmon S.D."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Kaduce T.L."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Kaduce T.L."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Spector A.A."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Spector A.A."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Raj Gopal V."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/author | "Raj Gopal V."xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/date | "2006"xsd:gYear |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/date | "2006"xsd:gYear |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/name | "Prostaglandins Leukot. Essent. Fatty Acids"xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/name | "Prostaglandins Leukot. Essent. Fatty Acids"xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/pages | "169-177"xsd:string |
| http://purl.uniprot.org/citations/16820285 | http://purl.uniprot.org/core/pages | "169-177"xsd:string |